23andMe for Healthcare Professionals

Advancing patient health. Together.

23andMe has more than 5 million customers worldwide. Our Health + Ancestry Service allows individuals to acquire this information from the privacy of their own homes, without medical requisition.

Nearly 30% of consumers who undergo direct-to-consumer (DTC) genetic testing choose to share their reports with healthcare providers to inform conversations about their health.1,2,3 Our Healthcare Professionals community was created to help U.S. providers and their patients navigate genetics together in order to make important informed decisions about prevention, treatment and healthy living.

Join our community to receive important updates about new features and information about upcoming educational programs and engagement opportunities.

The 23andMe Medical Professionals site is not intended for individuals in the EU.

The promise of genetics for health and wellness.

Helping people access, understand and benefit from the human genome.


At 23andMe, we believe that when consumers engage with their genetics, they are able to play a more active role in their health. We also believe the human genome holds the promise of contributing to major breakthroughs in medical research efforts. We go beyond genetic testing to engage consumers in research with the goal of accelerating therapeutic development. ~80% of our customers consent to participate in research, making 23andMe an important study partner in pioneering research.

Direct-to-consumer genetics

The 23andMe Personal Genetic Service provides information and tools for individuals to learn about their DNA.

Research services

23andMe researchers and our collaborators make meaningful discoveries using genetic data and survey information.

Drug discovery

23andMe Therapeutics strives to use human genetic data to accelerate the discovery of novel treatments.

meets fda requirements

Genetic Health Risks*

10 reports

  • 10 reports including:
  • Hereditary Thrombophilia
  • Late-Onset Alzheimer's Disease
  • Parkinson's Disease
  • sample report
meets fda requirements

Carrier Status*

40+ reports

  • 40+ reports including:
  • Cystic Fibrosis
  • Sickle Cell Anemia
  • Hereditary Hearing Loss
  • sample report


35+ reports

  • 35+ reports including:
  • Ancestry Composition
  • Maternal & Paternal Haplogroups
  • Neanderthal Ancestry
  • sample report


5+ reports

  • 5+ reports including:
  • Deep Sleep
  • Lactose Intolerance
  • Genetic Weight
  • sample report


25+ reports

  • 25+ reports including:
  • Hair Loss
  • Sweet vs. Salty
  • Unibrow
  • sample report

Engaging reports, expanding knowledge.

The first and only company authorized by the FDA to provide personal Genetic Health Risk reports* and Carrier Status reports* directly to consumers.


What causes consumers to pursue DTC genetic testing? Motivations include obtaining health-related information, learning about genetic risk factors, being on the vanguard of a new technology, curiosity in genetics, contributing to research and investigating self-identity.4

For individuals interested in genetic health information, it’s important to note that the 23andMe experience is not intended to be a diagnostic tool. Our objective is not to detect disease, but to deliver genetic information in the most engaging and responsible way. Our Genetic Health Risk and Carrier Status reports may, in certain cases, provide valuable information for clinical management.

Explore our reports to better understand the types of information your patients receive and may share with you.


Questions? Contact us at medical@23andme.com.

The 23andMe PGS test uses qualitative genotyping to detect clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. The relevance of each report varies based on ethnicity.  Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. Our carrier status reports can be used to determine carrier status, but cannot determine if an individual has two copies of any genetic variant.  These carrier reports are not intended to tell an individual anything about risk for developing a disease in the future or anything about the health of a fetus, or newborn child’s risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk.   These reports are intended to provide genetic information that can be used to inform lifestyle decisions and conversations with healthcare professionals, but are not intended to diagnose disease, determine medical treatment or medical intervention including whether to  take a medication or how much of a medication to take, or tell the user anything about their current state of health. Any diagnostic or treatment decisions must be based on confirmatory prescription testing and/or other information that you determine to be appropriate for your patient, such as additional clinical testing and other risk factors that may affect individual risk and health care.

For important information and limitations regarding other genetic health risk reports and carrier status reports, visit  https://www.23andme.com/test-info/.

1. Darst BF, et al., Health Commun (2014) 

2. Kaufman DJ, et al., J Genet Couns (2012) 

3. van der Wouden CH, et al., Ann Intern Med (2016) 

4. Turrini and Prainsack, Appl Transl Genom (2016)